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Abstract 
Purpose: The accumulation of wound fluid known as seroma in the chest cavity following breast surgery is a com‑
mon occurrence that can persist for many weeks. While the pro‑inflammatory composition of seroma is well estab‑
lished, there has been remarkably little research to determine whether seroma contains pro‑oncogenic factors, and 
whether this is influenced by previous malignant disease.
Methods: We developed a clinical trial in which we obtained post‑surgical seroma fluids from women with benign 
or malignant disease 1 or 2 weeks following lumpectomy or mastectomy. We conducted an analysis of more than 80 
different cytokines, chemokines and growth factors.
Results: We found that surgical cavity seroma from breast cancer patients has a higher expression of key tumor‑pro‑
moting cytokines and lower expression of important tumor‑inhibiting factors when compared to benign lesions from 
non‑cancer patients. Patients with high body mass index also had higher levels of leptin regardless of malignancy.
Conclusions: We conclude that the breast post‑surgical tumor cavity contains factors that are pro‑inflammatory 
regardless of malignant or benign disease, but in malignant disease there is significant enrichment of additional 
pro‑oncogenic chemokines, cytokines and growth factors, and reduction in tumor‑inhibiting factors. These results are 
consistent with tumor conditioning of surrounding normal stromal tissue and creation of a pro‑oncogenic environ‑
ment that persists long after surgical removal of the tumor.
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Background
Post-operative accumulation of seroma in the surgical 
cavity following breast cancer surgery varies in incidence 
from 2.5 to 51 % of patients (Siegel et al. 2015). In breast 
cancer, seroma is defined as serous fluid that collects in 
the dead space of the post-mastectomy skin flap, axilla, or 
breast following breast-conserving surgery (Agrawal et al. 
2006). Seroma formation is a common consequence of 
surgical excision, whereby empty space devoid of breast 
tissue elicits an inflammatory wound healing response 
with subcutaneous accumulation of serous fluid (Agrawal 
et  al. 2006). Analysis of seroma has shown that it is an 
inflammatory exudate, classically seen in the first phase 
of wound repair (McCaul et al. 2000).
While most seroma research is focused on the asso-
ciation with increased infection or its effect on cosme-
sis (Mukesh et  al. 2012), there has been little research 
on the potential pro-oncogenic composition of seroma 
fluid itself. Rather, correlations have been made between 
wound healing and tumor development, supported by 
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observations that chemically initiated or oncogene-
expressing cells can develop tumors more efficiently 
when transplanted into hospitable wound-healing stroma 
than in non-wound stroma (Hofer et  al. 1998). Moreo-
ver, one study found that patients with wound complica-
tions at primary surgery had an increased risk of systemic 
recurrence of breast cancer (Murthy et  al. 2007). It has 
also been shown that both overall survival and distant 
metastasis-free survival are significantly reduced in 
patients whose tumors express a wound-response signa-
ture compared to tumors that do not express this signa-
ture (Chang et  al. 2005). There are various mechanisms 
by which wounding can promote tumor development. 
Among these possibilities, seroma fluid has been shown 
to possess biological activities such as the ability to 
increase cancer cell proliferation, migration and invasion 
(Belletti et al. 2008; Tagliabue et al. 2003). The cytokines, 
chemokines and growth factors in seroma fluid that reg-
ulate these biological activities, however, have not been 
well characterized.
It is well established that tumors interact with and alter 
the surrounding stroma, and that such interactions are 
critical for tumor progression (Junttila and de Sauvage 
2013). Given that seroma is derived from the wound-
healing response of tumor-adjacent stroma, we asked 
whether seroma derived from the excision of benign 
tumors differs from that of malignant tumors, as malig-
nant and benign tumors may activate or influence the 
adjacent stroma and infiltrating immune cells differently. 
Here we show that surgical cavity seroma from breast 
cancer patients has a higher expression of certain tumor-
promoting cytokines, including GRO, ENA-78/CXCL5 
and TIMP-2, and lower expression of tumor-inhibiting 
cytokines IGFBP-1, IL-16, IFN-γ, IL-3 and FGF-9, when 
compared to seroma from non-cancer patients.
Patients and methods
Patients and sample collection
Post-surgical seroma fluids from women who had under-
gone either lumpectomy or mastectomy breast surgery 
were collected at week 1 or 2 post-surgery by percuta-
neous aspiration. The clinical protocol (NYU 09-0031) 
received institutional review board approval at NYU-
Langone Medical Center and Bellevue Hospital. All 
patients provided signed informed consent to partici-
pate in the study and seroma fluid for the protocol. The 
study was opened in February 2010 and closed to accrual 
in September 2013. A total of 296 patients were accrued 
to this study, however only 79 developed a clinically 
detectable and symptomatic seroma by week 1 or 2 post-
surgery. Of these patients, in 59 cases an adequate fluid 
sample was obtained to conduct the proposed molecu-
lar studies. After pathological examination, 24 patients 
were classified as having benign disease (fibroadenomas 
or benign microcalcifications). The remaining 35 patients 
had post-surgical pathologically confirmed malignant 
disease (invasive ductal carcinoma, lobular carcinoma). 
Patients were classified as ER/PR positive based on a cut 
off score of ≥2 % by IHC staining. Table 1 describes the 
clinical and pathologic characteristics of patients who 
participated in this study. After collection, seroma flu-
ids were centrifuged at 1500  rpm for 10  min at 4  °C to 
remove debris. Supernatants were aliquoted and stored 
at −80 °C until analysis.
Antibody‑based protein array system
All 59 seroma specimens were analyzed three times using 
RayBio™ Human Cytokine Array V membranes (Nor-
cross, GA, USA, cat. # AAH-CYT-5) according to manu-
facturer instructions. The array simultaneously detects 
80 different cytokines, chemokines and growth factors 
by a quantitative immunoblot sandwich assay. Cytokine 
array membranes were incubated in blocking buffer for 
30 min at room temperature and subsequently incubated 
Table 1 Patient characteristics
Benign Malignant
No. (%) No. (%)
No. 24 40.7 35 59.3
Age, years
 <55 19 79.2 8 22.9
 ≥55 5 20.8 27 77.1
Tumor size N/A
 pT1 (≤2 cm) 28 80
 pT2 (2–5 cm) 5 14.3
 pT3 (>5 cm) 2 5.7
Lymph node status N/A
 Negative 29 85.3
 Positive 5 14.7
Histological grade N/A
 1 6 18.2
 2 18 54.5
 3 9 27.3
Estrogen receptor status N/A
 Negative 2 5.9
 Positive 32 94.1
Progesterone receptor status N/A
 Negative 4 11.8
 Positive 30 88.2
HER2 status N/A
 0 5 15.2
 1+ 22 66.7
 2+ 5 15.2
 3+ 1 3
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with 1 ml of undiluted seroma fluid for 2 h at room tem-
perature. Membranes were washed in washing buffer 
and incubated with 1  ml of biotin-conjugated detection 
antibodies overnight at 4  °C. Thereafter, membranes 
were washed and incubated with 2  ml of streptavidin-
horseradish peroxidase at room temperature for 2  h. 
Membranes were developed using enhanced chemilumi-
nescence, visualized on X-ray film at multiple exposures 
in the linear sensitivity range (Genemate, catalog no. 
F-9023-8X10), scanned and spots quantified using densi-
tometric software Image J (NIH).
Array data normalization and statistical analyses
Positive control signals on each array were used for signal 
normalization according to manufacturer instructions. 
Graphing and statistical tests were performed using 
GraphPad Prism 6.0 software (San Diego, CA, USA). P 
values between two groups (benign, malignant) were 
calculated using an unpaired Student t-test. Multiple 
group analyses used one-way ANOVA and Tukey multi-
ple comparison tests. Correlation of cytokine, chemokine 
and growth factor expression with clinical-pathological 
parameters was determined using Pearson’s correlation 
analysis. A P value of <0.05 was considered to be statisti-
cally significant. All data are presented as mean ± SEM. 
Cellular processes associated with factors present in 
seroma fluid were determined using the NIH David 




Post-surgical seroma was collected from patients under-
going first time breast surgery for benign lesions or malig-
nant tumors. Descriptive characteristics of patients are 
provided in Table 1. There were 24 patients with benign 
disease (40.7 % of patients, average age 46 years) and 35 
patients with malignant disease (59.3 % of patients, aver-
age age 63 years). Malignant tumor size stage distribution 
was 80 % pT1, 14.3 % pT2, and 5.7 % pT3. Lymph node 
status was established for all but one patient with malig-
nant disease: 14.7 % lymph node positive, 85.3 % lymph 
node negative. Histological tumor grade was established 
for all but two patients with malignant disease: 18.2  % 
grade 1, 54.5 % grade 2, and 27.3 % grade 3. The major-
ity of malignant tumors were ER/PR positive (94.1 and 
88.2 %, respectively), and Her2 negative (81.9 %).
Factors in common in seroma from benign and malignant 
lesions
The signal intensity for each factor was quantified for all 
patient seroma samples using Image J densitometry anal-
ysis the array data were normalized based on the average 
positive control signal intensity for each array. The mean 
signal intensities of every spot were further corrected for 
local background effects. The collective data of factor 
expression profiles from benign (n = 24) and malignant 
(n = 35) seroma specimens are shown (Fig. 1a). From the 
80 cytokines that were assayed, 28 were highly expressed 
in seroma fluid derived from both benign and malignant 
lesions (Fig.  1a). The most highly expressed cytokines 
common to both benign and malignant seromas were 
IL-6, IL-8, MCP-1/CCL2, angiogenin, osteopontin, 
NAP2/CXCL7, TIMP-1, TIMP-2, RANTES/CCL5, 
IGFBP-1, IGFBP-2, GRO, OSM, eotaxin-2/CCL24, IL-10, 
MIP-1β/CCL4, VEGF, ENA-78/CXCL5, GDNF, LIF, 
PIGF, IL-3, IL-16, MCSF, HGF, MDC/CCL22, TGF-β2 
and leptin.
To establish the functional relevance of these enriched 
factors in seroma fluid, results were subjected to Gene 
Ontology and Pathway analysis using NIH David Soft-
ware. The majority of factors in common defined cellular 
processes associated with wound healing and inflam-
matory responses in both benign and malignant seroma 
(Fig.  1b). However, the profile present in post-surgical 
seroma determined here also contains factors with 
established tumor-promoting biological effects regard-
less of original benign or malignant disease. These fac-
tors include IL-6, IL-8 and MCP-1/CCL2 that have been 
shown to possess strong pro-proliferative and pro-onco-
genic biological activities (Balkwill and Mantovani 2001).
Malignant seroma has higher expression 
of tumor‑promoting cytokines and lower levels 
of tumor‑inhibiting factors than benign seroma
Next, we established whether factors were differentially 
expressed between seroma fluid from malignant versus 
benign post-surgical cavities. Of the 80 factors assayed, 
9 biologically important factors were differentially 
expressed. In particular, growth-regulated protein (GRO), 
ENA-78/CXCL5, TIMP-2, and leptin were strongly up-
regulated in malignant seroma, whereas IGFBP-1 (insu-
lin-like factor binding protein-1), IL-3, IFN-γ, FGF-9 and 
IL-16 were down-regulated in malignant versus benign 
seroma fluid (Figs.  2a, b,   3a–c). Cytokine comparisons 
between the benign and malignant groups were cross-
analyzed with non-tumor associated variables that might 
affect cytokine expression and were also differentially 
expressed between the two groups. These were examined 
as independent variables associated with factor differ-
ences. These included association between factor levels 
and body mass index (BMI), and the time point of seroma 
collection post-surgery (Table  1; Fig.  2c), tumor grade, 
HER2 status and patient age. Since 94 % of malignant dis-
ease patients were ER+, that could not be studied as an 
independent variable.
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Leptin expression has been well established to corre-
late positively with high BMI (Monti et al. 2006). Leptin 
was elevated in malignant seroma samples compared 
to benign seromas (Fig.  2b). However, BMI distribution 
was not equal between benign and malignant patients, 
with a greater number of high BMI patients (BMI ≥25) 
in the malignant rather than the benign group (63.3 and 
33.3  % respectively) (Fig.  2c). We investigated whether 
the differential expression of leptin between the two 
groups was dependent or independent of BMI. A Pear-
son correlation analysis of leptin expression and BMI for 
all seroma specimens was performed, demonstrating a 
significant positive correlation between leptin levels and 
BMI (r = 0.6422, p < 0.0001; Fig. 2d). None of the other 
factors showed a significant correlation with BMI (Addi-
tional file 1: Fig. S1). We therefore analyzed leptin levels 
between benign and malignant seromas in BMI-matched 
groups, separating the seroma samples into two groups, 
normal weight (BMI <25) and overweight plus obese 
(BMI ≥25). When re-analyzed in this manner, there were 
no significant differences in leptin expression between 
the BMI-matched benign and malignant seroma samples, 
indicating that elevated leptin levels are not indepen-

























































































































































































Highly enriched cytokines, chemokines and growth factors 
Cytokines 




Positive regulation of cell differentiation
Positive regulation of developmental processes
Cell migration/motility
Negative regulation of cell proliferation
Positive regulation of cell communication
Regulation of apoptosis/programmed cell death






Regulation of cell proliferation
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b
Fig. 1 Cytokines, chemokines and growth factors, associated with the wound healing response signature are highly expressed in both benign 
and malignant breast seroma fluid. a Quantification of array membranes. Mean levels from three independent studies of cytokines, chemokines 
and growth factors expressed in seroma fluid from benign (n = 24) vs. malignant (n = 35) patients are shown. b Functional analysis of cytokine, 
chemokine, and growth factor profiles from benign and malignant post‑surgical seroma. Functional analysis indicates seromas are associated with 
wound healing related cellular processes
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We also determined whether time of seroma collection 
post-surgery influenced cytokine expression. A Pearson 
correlation analysis compared expression of each of the 
nine factors identified above and the time of seroma col-
lection post-surgery. Seven of the nine factors did not 
show a significant correlation between their expression 
and time of seroma collection and therefore could be 
analyzed collectively (Additional file  1: Fig. S2). How-
ever, IL-16 and IGFBP-1 did demonstrate time-depend-
ent expression, both showing a significant decrease 
in expression with increased interval of time post-
surgery (IL-16: r  =  −0.6082, p  <  0.0001 and IGFBP-1: 
r = −0.3295, p = 0.0132) (Fig. 3d, e). Consequently, for 
IL-16 and IGFBP-1, seroma samples were separated into 
two groups—those collected within the first week post-
surgery, likely corresponding to the inflammatory and 
proliferation phases of wound healing (≤8 days, n = 14 
benign, n = 14 malignant) and those collected after the 
first week post-surgery, likely to correspond to the tis-
sue remodeling phase of wound healing (>8 days, n = 10 
benign, n =  18 malignant). With this adjustment it was 
found that IL-16 was significantly down-regulated in 
malignant seroma compared to benign seroma col-
lected within the first week post-surgery (p = 0.0328), a 
Leptin ungrouped 
2-PMITENA-78ORG
BMI n (%) 
Benign  < 25 12 (66.7%) 
25-29.9 4 (22.2%) 
≥ 30 2 (11.1%) 
Malignant < 25 11 (36.7%) 
25-29.9 10 (33.3%) 


















































































































Fig. 2 Factors significantly up‑regulated in malignant vs. benign seroma profiles. a Relative expression of cytokines up‑regulated in malignant 
post‑operative seroma fluid compared to benign seroma. b Leptin expression in benign and malignant seroma fluid presented collectively and as 
BMI‑matched groups. c Distribution of BMI among patients in benign and malignant groups. d Pearson correlation analysis showing a significant 
positive correlation of leptin expression with BMI [Pearson r = 0.6422; p < 0.0001, n = 48 (all benign and malignant seroma samples where data is 
available)]
















































































































































































Fig. 3 Factors down‑regulated in malignant vs. benign seroma profiles. a Relative expression of cytokines down‑regulated in malignant post‑
operative seroma fluid compared to benign seroma. b IL‑16 expression in benign and malignant seroma fluid presented collectively and at specific 
collection time‑points post surgery (group 1 = collection time point ≤8 days and group 2 = collection time‑point >8 days). c IGFBP‑1 expression 
in benign and malignant seroma fluid presented collectively and at specific collection time‑points post surgery (group 1 = collection time point 
≤8 days and group 2 = collection time‑point >8 days). d Pearson correlation analysis showing a significant negative correlation of IL‑16 expression 
and collection time‑point of seroma post‑surgery [Pearson r = −0.6082; p < 0.0001, n = 54 (all benign and malignant seroma samples where data is 
available)]. e Pearson correlation analysis showing a significant negative correlation of IGFBP‑1 expression and collection time‑point of seroma post‑
surgery [Pearson r = −0.3295; p = 0.0132, n = 56 (all benign and malignant seroma samples where data is available)]
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difference not observed in seroma collected at later time 
points (p =  0.2011) (Fig.  3b). IGFBP-1 was significantly 
down-regulated in seroma from malignant lesions com-
pared to seroma from benign lesions collected after the 
first week post-surgery (p = 0.0085), a difference not seen 
in seroma collected within the first week (p  =  0.3501) 
(Fig. 3c).
In summary, having accounted for variables that 
might introduce bias in the results of the comparison of 
cytokine expression between post-surgical seroma sam-
ples derived from benign and malignant patients, three 
factors (GRO, ENA-78, TIMP-2) were found to be up-
regulated (Fig. 2a) and five factors (IGFBP-1, IL-3, IFN-γ, 
FGF-9, IL-16) were down-regulated (Fig. 3a–c) in seroma 
fluid from breast cancer patients compared to non-can-
cer patients. The well-established biological activities of 
these differentially expressed cytokines might causally 
link them to local recurrence and metastasis at the breast 
tumor surgical wound-site. In fact, the cytokines that 
were up-regulated in malignant versus benign seroma 
samples have all been shown to orchestrate key tumor-
promoting biological activities in breast cancer (Table 2). 
Moreover, cytokines down-regulated in malignant com-
pared to benign seromas orchestrate various tumor-
inhibiting biological activities (Table 2).
Relationship between cytokines and clinical‑pathological 
features
We assessed whether there are statistically significant 
associations between the eight differentially expressed 
cytokines and specific clinical-pathological features in 
the malignant seroma patient group. No statistically sig-
nificant correlations were found between any of the eight 
factors and common clinical-pathological features exam-
ined, including tumor grade and HER2 status (Additional 
file  1: Figs. S3, S4), although certain trends were noted. 
For instance, ENA-78 trended towards increased expres-
sion with increasing tumor grade (Additional file 1: Fig. 
S3) and IL-3 trended towards decreased expression with 
increasing Her2 overexpression (Additional file  1: Fig. 
S4).
Discussion
Seroma fluid has been shown to promote various pro-
tumorigenic processes such as cancer cell proliferation, 
migration, invasion and acquisition of stem-like pheno-
types (Belletti et al. 2008; Segatto et al. 2014). This raises 
the possibility that tumor-promoting biological factors 
might exist in seroma fluid, although a comprehensive 
analysis of the cytokines, chemokines and growth fac-
tors present in seroma fluid has not yet been conducted. 
Using single marker ELISA assays, several studies showed 
that breast seroma fluid contains inflammatory cytokines 
IL-6, IL-2 and IL-1β (Al-Gaithy 2013). To conduct a more 
exhaustive analysis, a profile of the proteins present in 
seroma fluid derived from benign and malignant breast 
lesions was obtained using cytokine array that charac-
terizes 80 different cytokines, chemokines and growth 
factors simultaneously. We have shown that irrespective 
of benign or malignant tumor type, breast seroma fluid 
is highly enriched in factors that are involved in wound 
healing, inflammatory responses and tissue remodeling 
processes. Since seroma fluid is a product of the wound 
healing response this result was expected. However, our 
studies have identified a panel of factors present in breast 
seroma fluid, which have not been previously established. 
These findings give a plausible explanation for the tumor-
promoting biological effects of seroma fluid, as it is 
highly enriched with many factors such as IL-6, IL-8 and 
MCP-1/CCL2 that have been shown to possess strong 
pro-proliferative and pro-oncogenic biological activities 
(Balkwill and Mantovani 2001).
Of the eight cytokines that were differentially expressed 
between seroma fluid from breast cancer and non-cancer 
patients, three were specifically up-regulated in malig-
nant seroma fluid (GRO, ENA-78/CXCL5 and TIMP-2). 
These factors have been demonstrated to promote vari-
ous pro-tumorigenic activities in breast cancer, impli-
cating a potential importance of these factors in local 
recurrence and metastasis of malignant breast tumors. 
GRO chemokines which consist of three isoforms GRO-
α, GRO-β and GRO-γ, also known as CXCL1, CXCL2 
and CXCL3 are established granulocyte chemo-attract-
ants (Owen and Mohamadzadeh 2013). The GRO factors 
have recently been shown to orchestrate tumor-promot-
ing biological activities in breast cancer. For instance, 
GRO chemokines support the growth of triple-negative 
breast cancer cell lines (Hartman et  al. 2013) and pro-
mote breast cancer metastasis and resistance to chemo-
therapy (Acharyya et al. 2012). ENA-78/CXCL5 is closely 
related to the GRO chemokines, as they are all ELR+CXC 
chemokines characterized by a Glu-Leu-Arg (ELR) motif 
preceding the CXC sequence and signal via a common 
receptor CXCR2 (Strieter et  al. 1995). Similar to GRO 
chemokines, ENA-78/CXCL5 chemo-attracts and acti-
vates neutrophils (Owen and Mohamadzadeh 2013) and 
has also been shown to possess tumor-promoting bio-
logical activities. For example, in breast cancer, ENA-78/
CXCL5 promotes breast cancer cell migration and inva-
sion (Hsu et al. 2013), and is reported to stimulate can-
cer stem cell (CSC) activity (Liu et al. 2011). ENA-78 has 
been associated with poor prognosis, tumor progression, 
cell proliferation, migration and invasion in other cancer 
types as well (Kawamura et al. 2012; Li et al. 2011).
Tissue inhibitor of metalloproteinases-2 (TIMP-2) 
was also specifically up-regulated in malignant breast 
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seroma samples in our study. TIMP-2 is known to regu-
late matrix metalloproteinase-2 (MMP-2), which plays a 
role in extra-cellular matrix proteolysis (Ellerbroek and 
Stack 1999). Traditionally thought of as an MMP-2 inhib-
itor, it has been demonstrated that TIMP-2 actually plays 
a dual role in regulating MMP-2 activity and can either 
initiate or inhibit its activity (Lu et  al. 2004; Shen et  al. 
2010). Due to its dual roles, TIMP-2 has been reported to 
have both pro-tumorigenic and anti-tumorigenic roles in 
cancer. For example, by inhibiting the activity of MMP-2, 
TIMP-2 can block tumor cell invasion (Albini et al. 1991) 
thereby acting an anti-tumorigenic factor. However, sev-
eral studies have also highlighted the pro-tumorigenic 
activities of TIMP-2. TIMP-2 was shown to promote 
breast tumor metastasis by regulating MMP-2-mediated 
breast cancer cell transmigration through lung microvas-
cular endothelial cells (Shen et al. 2010). Moreover, using 
a human glioblastoma cell line model, it was demon-
strated that up-regulation of TIMP-2 promotes MMP-2 
activation and subsequent glioblastoma cell invasion (Lu 
et  al. 2004). In melanoma cells TIMP-2 over-expression 
is sufficient to increase NF-κB activity and protect cells 
from apoptosis (Sun and Stetler-Stevenson 2009). Fur-
thermore, high levels of TIMP-2 are correlated with 
adverse prognosis in breast cancer (Remacle et al. 2000). 
In our study, TIMP-2 was more elevated in malignant 
seroma samples than benign samples, but its significance 
is still to be determined. Mechanistic studies are needed 
to define the role of TIMP-2 in breast cancer seroma.
We found five cytokines that were down-regulated 
in seroma fluid from malignant versus benign lesions 
(IGFBP-1, IL-3, IFN-γ, FGF-9 and IL-16). Most of these 
cytokines have been shown to possess anti-tumorigenic 
properties. Their down-regulation in malignant seroma 
could conceivably be relevant to the risk of local recur-
rence and metastasis in malignancies. IGFBP-1 is one of 
six homologous proteins that specifically bind to insulin-
like growth factor (IGF)-I and IGF-II (we also analyzed 
IGFBP-2, 3 and 4 and their expression was not different 
between benign and malignant seroma samples). The 
binding of IGFBP-1 to IGFs prevents their interaction 
with their receptors, and inhibits the mitogenic and met-
abolic actions of IGFs (Lee et al. 1993). Consistent with its 
physiological function, in breast cancer IGFBP-1 has also 
been shown to inhibit IGF-mediated cell proliferation 
(Yee et  al. 1994) and breast cancer cell motility (Zhang 
and Yee 2002). Our data supports the findings of Subra-
manian et  al. (2007), who showed that IGFBP-1 mRNA 
levels were significantly lower in malignant breast tissue 
compared to normal breast tissue samples (protein levels 
were not examined). Given that IGFBP-1 possesses tumor 
suppressive roles in breast cancer, its down-regulation in 
malignant seroma suggest that it might be involved in 
promoting malignant tumor progression.
Interleukin-3 (IL-3), also known as multi-lineage-
colony stimulating factor (Multi-CSF), is a cytokine 
that supports the growth and differentiation of a broad 
range of hematopoietic cells types including hematopoi-
etic stem cells, macrophages and lymphoid cells and 
enhances immune responses during disease and infection 
(Korpelainen et  al. 1996). In accordance with its estab-
lished physiological roles, IL-3 was found to increase 
tumor immunogenicity in mouse models of lung cancer 
and fibrosarcoma by promoting development of tumor 
reactive cytotoxic T cells and by promoting infiltration 
and activation of anti-tumorigenic macrophages (Pulaski 
et al. 1996). A role for IL-3 in breast cancer has not yet 
been established. However, our study found that IL-3 
was down-regulated in malignant seroma samples com-
pared to benign seromas. Given the importance of IL-3 
in augmenting immune responses, it is possible that its 
down-regulation in malignant seromas might reflect 
a mechanism by which invasive breast cancers escape 
immune surveillance.
IFN-γ is a pleiotropic cytokine that is involved in 
nearly all immune and inflammatory responses including 
growth, differentiation and activation of T-cells, B-cells, 
macrophages and natural killer (NK) cells (Schroder et al. 
2004). IFN-γ has anti-tumorigenic activities, including 
tumor immune-surveillance (Dunn et  al. 2006; Kaplan 
et  al. 1998), tumor cytostatic/cytotoxic effects (Chawla-
Sarkar et  al. 2003) and decreases tumor angiogenesis 
(Beatty and Paterson 2001). With respect to breast can-
cer, IFN-γ has anti-proliferative effects on breast cancer 
cell lines (Gooch et al. 2000). It has also been shown that 
IFN-γ-induced signaling is reduced in B-cells isolated 
from breast cancer patients compared to those from 
healthy controls, and impaired IFN-γ signaling was evi-
dent in early and late state stage breast cancers (Critch-
ley-Thorne et  al. 2009). The well-established role of 
IFN-γ as an anti-tumorigenic cytokine is consistent with 
our data demonstrating its down-regulation in malignant 
versus benign seromas.
FGF9 is a growth factor that is involved in a variety of 
biological processes including embryonic development, 
cell proliferation, differentiation and migration (Goetz 
and Mohammadi 2013). The role of FGF-9 in breast can-
cer has not been well established, although one study 
found that estrogen could expand the breast CSC popula-
tion through a paracrine mechanism that involved FGF9 
(Fillmore et al. 2010). We found that FGF9 is down-reg-
ulated in malignant compared to benign seroma, a puz-
zling finding. However, the function of FGF9 has not 
been well characterized in most cancers, and FGF9 could 
Page 10 of 11Valeta‑Magara et al. SpringerPlus  (2015) 4:483 
well have dual roles, as both a pro-and anti-tumorigenic 
factor whose function could be context/tissue dependent. 
Further studies are needed to establish the role of FGF-9 
in breast seroma.
Interleukin-16 (IL-16) is a CD4+ T-cell chemo-attract-
ant that also promotes T-cell proliferation, modulates 
inflammatory and immune responses and promotes 
B-cell differentiation (Wilson et  al. 2004). The role of 
IL-16 in cancer has been well studied in hematologi-
cal malignancies, where its levels are elevated compared 
to healthy individuals (Atanackovic et  al. 2012; Rich-
mond et al. 2011). IL-16 is growth-promoting in multiple 
myeloma and cutaneous T-cell lymphoma (Atanackovic 
et al. 2012; Richmond et al. 2011). However, IL-16 func-
tion in solid tumors has not been studied. Given that 
IL-16 is involved in T-cell recruitment and proliferation 
and modulates other immune responses, it might pro-
mote breast tumor immune surveillance and function as 
a tumor suppressor, accounting for its down-regulation 
in breast cancer seroma. Further studies are needed to 
establish the role of IL-16 in breast seroma.
Conclusion
In conclusion, we conducted an exhaustive analysis of 
the cytokines, chemokines and growth factors present in 
benign and malignant breast seroma fluid, showing that 
after surgery the cavity is enriched in factors involved 
in wound healing, inflammation and tissue remodeling 
processes. Moreover, some of the cytokines, chemokines 
and growth factors enriched in seroma fluid are known 
enhancers of tumor development and progression. 
Future studies should be conducted with a larger cohort 
of patients undergoing breast surgery for benign and 
malignant lesions to confirm these findings. The differ-
ential expression of the eight factors between benign and 
malignant seroma fluid offers research hypotheses to be 
explored further to determine their role in breast tumor 
progression, local recurrence and metastasis.
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Additional file 1: Figure S1. Correlation between cytokine expres‑
sion and BMI in post‑surgical seroma fluid. Pearson correlation analysis 
showing there was no relationship between expression of any these 
cytokines and BMI. Figure S2. Correlation between cytokine expression 
and collection time‑point of seroma post‑surgery. Pearson correlation 
analysis showing there was no relationship between expression of any 
these cytokines and seroma time of collection post‑surgery. Figure S3. 
Comparison of cytokine expression and tumor grade in seroma fluid 
derived from patients in the malignant group. There were no significant 
associations between cytokine expression and tumor grade for all the 
factors studied. Figure S4. Comparison of cytokine expression and HER2 
status in seroma fluid derived from patients in the malignant group. There 
were no significant associations between cytokine expression and HER2 
status for all the factors studied.
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